HALO analyst estimates
Halozyme (HALO) analyst ratings, the average price target and its range, and every firm's latest call.
HALO analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 16, 2026 | Stifel Nicolaus | H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO) | $130.00 |
| Oct 8, 2026 | H.C. Wainwright | Halozyme price target raised to $130 from $115 at H.C. Wainwright | $130.00 |
| Aug 10, 2026 | Wells Fargo | Halozyme price target raised to $95 from $75 at Wells Fargo | $95.00 |
| Aug 7, 2026 | H.C. Wainwright | Halozyme price target raised to $115 from $95 at H.C. Wainwright | $115.00 |
| Aug 7, 2026 | Leerink Partners | Leerink upgraded Halozyme to Outperform on growth, market leadership | $110.00 |
| Aug 7, 2026 | Morgan Stanley | Halozyme price target raised to $105 from $93 at Morgan Stanley | $105.00 |
| Jun 3, 2026 | UBS | Benchmark Reiterates Buy Rating on Halozyme Therapeutics (HALO) on Near-Term Potential | $90.00 |
| May 12, 2026 | Morgan Stanley | Halozyme price target lowered to $93 from $96 at Morgan Stanley | $93.00 |
| Apr 29, 2026 | H.C. Wainwright | Halozyme price target raised to $95 from $90 at H.C. Wainwright | $95.00 |
| Apr 21, 2026 | Morgan Stanley | Halozyme price target raised to $96 from $94 at Morgan Stanley | $96.00 |
| Feb 19, 2026 | Wells Fargo | Halozyme price target raised to $75 from $65 at Wells Fargo | $75.00 |
| Feb 19, 2026 | Morgan Stanley | Halozyme price target raised to $94 from $78 at Morgan Stanley | $94.00 |
| Jan 8, 2026 | Morgan Stanley | Halozyme price target lowered to $75 from $79 at Morgan Stanley | $75.00 |
| Dec 4, 2025 | Goldman Sachs | Goldman Sachs Downgrades Halozyme Therapeutics (HALO) to Sell 'as we approach peak revenue' | $56.00 |
| Dec 4, 2025 | UBS | Halozyme downgraded to Sell from Neutral at Goldman Sachs | $56.00 |
- 9 firms rate HALO: 6 buy, 3 hold, 0 sell.
- The average price target is $110.00 from 6 analysts, from $90.00 to $130.00.
Updated 2026-11-02 18:27 UTC